Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Ovarian Cancer: early-phase trial registry
4 of 7 indexed Recurrent Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Ovarian Cancer: 7 US clinical trials tracked, 4 recruiting.
Recurrent Ovarian Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Marc Goodman, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-ovarian-cancer
OPEN 4 | RECR 57% | LATE 0 | EARLY 7 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Recurrent Ovarian Cancer lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Ovarian Cancer is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Recurrent Ovarian Cancer trials is spread across many organizations.
Marc Goodman accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Ovarian Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Recurrent Ovarian Cancer research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT03564340
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie
NCT06365853
Combination Therapy for Recurrent Ovarian Cancer
Sham Sunder Kakar
NCT05610735
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Lan Coffman
NCT05942300
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio
NCT05335993
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals
NCT01381861
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
Marc Goodman
NCT04457089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Ovarian Cancer page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Recurrent Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Marc Goodman sponsors the most Recurrent Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Marc Goodman's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Ovarian Cancer condition card totals 7 registered trials; most-linked intervention Carotuximab (TRC105); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.